SCHEMBL9923922

SCHEMBL9923922

O=S(=O)(c1ccc(F)cc1)N(Cc1ccc(F)c(C(F)(F)F)c1)c1nc2ccccn2c1Cl

nearest known ligand 0.51

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 17/20 0.51
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TRPV1 Q8NER1 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893451 0.95 TRPM8 (0.52) TRPM8ALOX15HSD17B10TRPV1
SCHEMBL9924013 0.90 TRPM8 (0.46) TRPM8ALOX15HSD17B10TRPV1
SCHEMBL9923920 0.85 TRPM8 (0.51) TRPM8TRPV1
SCHEMBL9924014 0.83 TRPM8 (0.42) TRPM8
SCHEMBL9923966 0.83 TRPM8 (0.53) TRPM8
SCHEMBL9893342 0.83 TRPM8 (0.44) TRPM8HSD17B10
SCHEMBL9923921 0.83 TRPM8 (0.50) TRPM8
SCHEMBL15631097 0.82 TRPM8 (0.53) TRPM8TRPV1
SCHEMBL9923993 0.82 TRPM8 (0.54) TRPM8TRPV1
SCHEMBL9924020 0.81 TRPM8 (0.54) TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed
WO-2012078994-A1 IMIDAZO [1, 2-A] PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 TRPM8 1/4885ALOX15 3730/4885HSD17B10 4747/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 TRPM8 1/4885ALOX15 3730/4885HSD17B10 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.